You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Resistance to Immunotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Melanoma, Metastatic Melanoma, Immunotherapy Trial (Pembrolizumab, Encorafenib, Binimetinib)

Not yet recruiting
  • Malignant Melanoma
  • +4 more
  • (no location specified)
Mar 31, 2022

Cancer Patients Trial in Jinan (Low-dose radiotherapy combined with conventional fractionated radiotherapy)

Recruiting
  • Cancer Patients
  • Low-dose radiotherapy combined with conventional fractionated radiotherapy
  • Jinan, In Shandong Province, China
    The First Affiliated Hospital of Shandong First Medical Universi
Jun 7, 2023

Advanced Melanoma

Enrolling by invitation
  • Melanoma
  • observational
  • Durham, North Carolina
    Duke University Medical Center
Aug 16, 2022

Microenvironment of Lung Cancer and Exploration of Mechanism of

Recruiting
  • Lung Cancer
  • Multiomics analysis
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

HCC Trial in Hong Kong (Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib)

Not yet recruiting
  • HCC
  • Zabadinostat (CXD101) and Geptanolimab
  • Lenvatinib and Sorafenib
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital
May 15, 2023

Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

Not yet recruiting
  • Metastatic Extracranial Malignant Solid Neoplasm
  • +3 more
  • Intestinal Low Dose Radiotherapy-1Gy
  • +3 more
  • Shantou, Guangdong, China
    Cancer Hospital, Shantou University Medical College
Oct 7, 2023

Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy Trial in Wuhan (CTV omitted or delineated)

Not yet recruiting
  • Advanced Non-Small Cell Squamous Lung Cancer
  • +2 more
  • CTV omitted or delineated
  • Wuhan, Hubei, China
    Hubei Cancer Hospital
Sep 7, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

l Science Network of Precision-based Immunotherapy for Primary

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
    • La Jolla, California
    • +6 more
    Jan 24, 2023

    Lymphoma, Leukemia, Myeloma Trial in Tampa (Resistance Training, Aerobic Exercise)

    Recruiting
    • Lymphoma
    • +2 more
    • Resistance Training
    • Aerobic Exercise
    • Tampa, Florida
      Moffitt Cancer Center
    Feb 28, 2023

    Quality of Life of Primary Solid Malignant Cancers Receiving

    Recruiting
    • Malignant Neoplasm
    • Solid tumor patients receiving immunotherapy for the first time were included in the study
    • Xi'an, Shanxi, China
      First Affiliated Hospitap of Xian Jiaotong University
    Feb 22, 2023

    Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction

    Not yet recruiting
    • Hiv
    • +5 more
    • differences in CD4 reconstruction
    • (no location specified)
    Sep 17, 2023

    Immunotherapy Trial in Heidelberg (Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab)

    Not yet recruiting
    • Immunotherapy
    • Fecal microbiota transfer
    • +4 more
    • Heidelberg, Baden-Württemberg, Germany
    • +1 more
    Jan 19, 2023

    Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

    Recruiting
    • Metastatic Melanoma
    • +3 more
    • Immune checkpoint inhibitor
    • Ljubljana, Slovenia
      Institute of Oncology Ljubljana
    May 17, 2023

    Cutaneous Melanoma Trial in Paris (Blood sample, Cutaneous melanoma biopsy)

    Recruiting
    • Cutaneous Melanoma
    • Blood sample
    • Cutaneous melanoma biopsy
    • Paris, Ile De France, France
      Dermatology department
    Oct 24, 2022

    Toxicities in Children and Adults With Cancer

    Active, not recruiting
    • Macrophage Activation Syndrome
    • Primary Hemophagocytic Lymphohistiocytosis
      • Bethesda, Maryland
        National Cancer Institute (NCI)
      Sep 17, 2022

      Primary CNS Lymphoma Trial in London (CD19CAR T-cells)

      Recruiting
      • Primary CNS Lymphoma
      • CD19CAR T-cells
      • London, United Kingdom
        University College London Hospital
      Jun 13, 2022

      Cervical Cancer = FIGO IIB and or Lymph Node Metastases Trial (Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab),

      Not yet recruiting
      • Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases
      • Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)
      • +2 more
      • (no location specified)
      Aug 16, 2022

      Immunotherapy in Locally Advanced or Oligometastatic NSCLC

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • induction therapy
      • Esslingen, Germany
        Klinikum Esslingen
      Aug 15, 2022

      Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)

      Recruiting
      • Ependymoma
      • +3 more
      • Augusta, Georgia
        Augusta University, Georgia Cancer Center
      Dec 16, 2022

      Bone Loss, Bone Loss, Age-related, Osteoporosis Trial (Resistance Training)

      Not yet recruiting
      • Bone Loss
      • +3 more
      • Resistance Training
      • (no location specified)
      Jul 17, 2023

      Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis Trial in Shanghai (a combination therapy)

      Not yet recruiting
      • Advanced Rectal Cancer
      • +3 more
      • a combination therapy including tislelizumab
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Nov 9, 2022

      Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial in Changsha (Genomic profiles detection,

      Recruiting
      • Lung Cancer, Non-small Cell
      • +4 more
      • Genomic profiles detection
      • circulating tumor DNA detection
      • Changsha, Hunan, China
        Department of Oncology, The Second Xiangya Hospital, Central Sou
      Oct 25, 2022

      Hepatocellular Carcinoma Trial in Yichang (Sintilimab)

      Recruiting
      • Hepatocellular Carcinoma
      • Yichang, Hubei, China
        Department of Medical Oncology, Central Hospital of Yichang City
      Sep 1, 2023

      Sexually Transmitted Infection, Chlamydia, Gonorrhea Trial (Point-of-care STI testing)

      Not yet recruiting
      • Sexually Transmitted Infection
      • +8 more
      • Point-of-care STI testing
      • (no location specified)
      Sep 12, 2022